about
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcomeAssociation between mutation of the NF2 gene and monosomy 22 in menopausal women with sporadic meningiomasPhenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality.Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool.The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis.Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis.Flow cytometry criteria for systemic mastocytosis: bone marrow mast cell counts do not always count.CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis.Cell-cycle distribution of different cell compartments in normal versus reactive bone marrow: a frame of reference for the study of dysplastic hematopoiesis.Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.Evaluation of the WHO criteria for the classification of patients with mastocytosis.Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis.Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion.Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterationsIncreased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approachMast cell-related disorders presenting with Kounis syndromeCLL-like B-lymphocytes are systematically present at very low numbers in peripheral blood of healthy adults.KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patientsAnalysis of gene variants in the GASH/Sal model of epilepsyFrequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis
P50
Q33158687-5AEF8665-5DFF-40D2-8D5B-75A02999F2DDQ33160609-F1E5997B-D016-48FE-923E-DF6355C26EB3Q34987900-8B4AEEF0-5180-442E-8175-1BBA09609951Q35025246-E186D8D7-54AB-4356-B84B-555B82401D89Q35028723-03F682D9-8814-434C-AC19-A1243FF8AF1DQ36619075-D7DC7C6B-C3BC-497B-BB58-038B74A00AA0Q38205501-0EA45635-5D1D-455B-9446-98C8D0C134D9Q38266219-F439B371-7D4E-483B-A6F5-F2F60E504E42Q41604021-BFA5F73B-6AAE-467D-8857-02F98F99DE1CQ44767953-9AEB8500-958E-43EA-B57D-1525DFDBE4FDQ44959863-C8E74B5D-9C4B-45B8-8206-9E171BCA9083Q46284172-1279B1BF-5650-4C2E-9F16-D820CEF5DE9BQ50484927-E7426A5C-97EC-472E-834C-B64BC7A5FAFCQ50492462-66FA67C0-0170-4C48-86EF-405B4D7E988CQ50533869-BC29E49B-2736-4CA6-B4A2-514ECDFAEA95Q50900052-C2BDE980-48DF-484A-8550-D7CAD5421A05Q51013817-ED467C92-7049-4E0B-9A28-889242BF26C1Q51505022-E757A89E-D423-4EF5-BEA9-FA271C8951A6Q51571187-223253A0-AF02-44B8-95E2-4414CAA2037EQ52750513-D3FFE334-B6D3-4475-937D-5F6A82E65DE8Q53093872-D8BF421A-D6C3-44C6-B82D-27AD20AC51F7Q54447022-3A360CFA-2D87-4723-88A2-0B3E11D23756Q58010072-A14CECCE-2CEB-4596-82CF-E2F92B202206Q60724766-C8976E9F-5571-460B-B630-D0AAC8F8E936Q61818962-188513DE-CA3B-4B5E-B33D-6B77C4B3684BQ61818964-AA02CE0B-6862-499F-8096-087039B89887Q61818977-5F0CF9CF-D3C1-4F2F-95E2-536E39C03617Q90305392-50484038-DDD5-4AA9-BC01-651A2FDB6AA9Q92450813-00437A1A-F7FB-4409-86F4-C526B6F3296C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
María Jara-acevedo
@ast
María Jara-acevedo
@en
María Jara-acevedo
@es
María Jara-acevedo
@nl
María Jara-acevedo
@sl
type
label
María Jara-acevedo
@ast
María Jara-acevedo
@en
María Jara-acevedo
@es
María Jara-acevedo
@nl
María Jara-acevedo
@sl
prefLabel
María Jara-acevedo
@ast
María Jara-acevedo
@en
María Jara-acevedo
@es
María Jara-acevedo
@nl
María Jara-acevedo
@sl
P106
P1153
26648725100
P21
P31
P496
0000-0001-7965-7512